[
  {
    "ts": null,
    "headline": "How analysts are reacting to RFK Jr. as Trump's HHS pick",
    "summary": "President-elect Donald Trump has selected Robert F. Kennedy Jr. for the position of Secretary of Health & Human Services (HHS). The appointment has drawn significant attention due to Kennedy Jr.'s controversial stance on vaccines, including his designation as one of the \"Disinformation Dozen\" during the COVID-19 pandemic. Following the announcement, vaccine-related stocks experienced a notable decline. Yahoo Finance Senior Health Reporter Anjalee Khemlani analyzes the implications of this appointment and shares reactions from market analysts regarding its potential impact on the healthcare sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith",
    "url": "https://finnhub.io/api/news?id=6bc4479869ef72c674a45e070824c8a3a5e89aa530277dc162144244d06b4d19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731705531,
      "headline": "How analysts are reacting to RFK Jr. as Trump's HHS pick",
      "id": 131380383,
      "image": "https://s.yimg.com/ny/api/res/1.2/XHufKm_W5Z24SVpgb3USsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-10/5f0acd20-a396-11ef-9e7e-3044e215c025",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "President-elect Donald Trump has selected Robert F. Kennedy Jr. for the position of Secretary of Health & Human Services (HHS). The appointment has drawn significant attention due to Kennedy Jr.'s controversial stance on vaccines, including his designation as one of the \"Disinformation Dozen\" during the COVID-19 pandemic. Following the announcement, vaccine-related stocks experienced a notable decline. Yahoo Finance Senior Health Reporter Anjalee Khemlani analyzes the implications of this appointment and shares reactions from market analysts regarding its potential impact on the healthcare sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith",
      "url": "https://finnhub.io/api/news?id=6bc4479869ef72c674a45e070824c8a3a5e89aa530277dc162144244d06b4d19"
    }
  },
  {
    "ts": null,
    "headline": "Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy",
    "summary": "MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.",
    "url": "https://finnhub.io/api/news?id=ea9c3361a2c4215109fff43f1510a777480464c36ce4f992deb7f905c948c128",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731699480,
      "headline": "Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy",
      "id": 131382951,
      "image": "https://media.zenfs.com/en/zacks.com/df847a6f57145ec8b42be7c65f980057",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.",
      "url": "https://finnhub.io/api/news?id=ea9c3361a2c4215109fff43f1510a777480464c36ce4f992deb7f905c948c128"
    }
  },
  {
    "ts": null,
    "headline": "The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business",
    "summary": "Even though Merck & Co., Inc.'s ( NYSE:MRK ) recent earnings release was robust, the market didn't seem to notice. Our...",
    "url": "https://finnhub.io/api/news?id=46850b0010861cedd0da13a42ec16bb719c3fd80b69f77d888b85999658faca9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731696457,
      "headline": "The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business",
      "id": 131387235,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Even though Merck & Co., Inc.'s ( NYSE:MRK ) recent earnings release was robust, the market didn't seem to notice. Our...",
      "url": "https://finnhub.io/api/news?id=46850b0010861cedd0da13a42ec16bb719c3fd80b69f77d888b85999658faca9"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=bac8693a264d804238b936ed729404134815a6e389c5be8985c40c127380b894",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731688500,
      "headline": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
      "id": 131414221,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=bac8693a264d804238b936ed729404134815a6e389c5be8985c40c127380b894"
    }
  },
  {
    "ts": null,
    "headline": "Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.",
    "summary": "President-elect Donald Trump taps Robert F. Kennedy Jr. to lead U.S. Health and Human Services Department (HHS). Vaccine stocks slide on the news.",
    "url": "https://finnhub.io/api/news?id=1cce2f929872693557a4ef1cd584e7ea153b346f2a62323f1f1ef636c705e0fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731681831,
      "headline": "Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.",
      "id": 131372045,
      "image": "https://s.yimg.com/ny/api/res/1.2/2W3zS7JNyNzoXwwNnEnlEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-11/d78a1dd0-a357-11ef-bfd7-7379c5ff40c5",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "President-elect Donald Trump taps Robert F. Kennedy Jr. to lead U.S. Health and Human Services Department (HHS). Vaccine stocks slide on the news.",
      "url": "https://finnhub.io/api/news?id=1cce2f929872693557a4ef1cd584e7ea153b346f2a62323f1f1ef636c705e0fa"
    }
  },
  {
    "ts": null,
    "headline": "Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)",
    "summary": "RAHWAY, N.J., November 15, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma (MPM).",
    "url": "https://finnhub.io/api/news?id=c53df72f6eef70200fae3a67e9a5d3929a145121bd9dc0c54fb9b55fd5ecc364",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731672900,
      "headline": "Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)",
      "id": 131387237,
      "image": "https://media.zenfs.com/en/business-wire.com/72210cd91dacf023747d1aa4030a1fa0",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 15, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma (MPM).",
      "url": "https://finnhub.io/api/news?id=c53df72f6eef70200fae3a67e9a5d3929a145121bd9dc0c54fb9b55fd5ecc364"
    }
  },
  {
    "ts": null,
    "headline": "Wolfe Research Initiates Coverage of Merck (MRK) with Peer Perform Recommendation",
    "summary": "Wolfe Research Initiates Coverage of Merck (MRK) with Peer Perform Recommendation",
    "url": "https://finnhub.io/api/news?id=c7e73f6bb648ed44ed5831244177751e44656d3e211d74173f09a7ffe92809e2",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731668313,
      "headline": "Wolfe Research Initiates Coverage of Merck (MRK) with Peer Perform Recommendation",
      "id": 131367495,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=c7e73f6bb648ed44ed5831244177751e44656d3e211d74173f09a7ffe92809e2"
    }
  },
  {
    "ts": null,
    "headline": "Amgen, Amazon.com Inc. share losses lead Dow's 288-point drop",
    "summary": "Amgen, Amazon.com Inc. share losses lead Dow's 288-point drop",
    "url": "https://finnhub.io/api/news?id=bc8b10995451e9e40a1762fab4c38047a23925398882afdc468c6ab42f3b8809",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731667560,
      "headline": "Amgen, Amazon.com Inc. share losses lead Dow's 288-point drop",
      "id": 131412967,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Amgen, Amazon.com Inc. share losses lead Dow's 288-point drop",
      "url": "https://finnhub.io/api/news?id=bc8b10995451e9e40a1762fab4c38047a23925398882afdc468c6ab42f3b8809"
    }
  },
  {
    "ts": null,
    "headline": "How To Invest $100,000 In Large Cap Stocks: A Tax-Efficient Advisor-Less Strategy",
    "summary": "This DIY market index strategy blends large-cap stocks and ETFs, plus tax loss harvesting. Read how you can save on fees and manage your own portfolio.",
    "url": "https://finnhub.io/api/news?id=8341c76eb768a3c3450127c2b3d77bebe3f33ada16d4b0b092714778146d3d1d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731664658,
      "headline": "How To Invest $100,000 In Large Cap Stocks: A Tax-Efficient Advisor-Less Strategy",
      "id": 131370892,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1887469204/image_1887469204.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "This DIY market index strategy blends large-cap stocks and ETFs, plus tax loss harvesting. Read how you can save on fees and manage your own portfolio.",
      "url": "https://finnhub.io/api/news?id=8341c76eb768a3c3450127c2b3d77bebe3f33ada16d4b0b092714778146d3d1d"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Amgen share losses lead Dow's 168-point drop",
    "summary": "Merck, Amgen share losses lead Dow's 168-point drop",
    "url": "https://finnhub.io/api/news?id=68d409a3fee1590d96f44b4fd62494cef5401b8be8f0e2bb95ef25e28b2d2080",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731663900,
      "headline": "Merck, Amgen share losses lead Dow's 168-point drop",
      "id": 131412972,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck, Amgen share losses lead Dow's 168-point drop",
      "url": "https://finnhub.io/api/news?id=68d409a3fee1590d96f44b4fd62494cef5401b8be8f0e2bb95ef25e28b2d2080"
    }
  },
  {
    "ts": null,
    "headline": "Merck: CHMP gives green light for Keytruda in pleural mesothelioma",
    "summary": "Merck announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for the approval of Keytruda , in combination with pemetrexed...",
    "url": "https://finnhub.io/api/news?id=4b8bc728a7f152bbcb13056c54e79cceea3e3e70de00c9a2e4f763c593b10ed8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731661636,
      "headline": "Merck: CHMP gives green light for Keytruda in pleural mesothelioma",
      "id": 131370153,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for the approval of Keytruda , in combination with pemetrexed...",
      "url": "https://finnhub.io/api/news?id=4b8bc728a7f152bbcb13056c54e79cceea3e3e70de00c9a2e4f763c593b10ed8"
    }
  },
  {
    "ts": null,
    "headline": "Merck Gets CHMP Backing of Keytruda in Malignant Pleural Mesothelioma",
    "summary": "By Colin Kellaher Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its blockbuster cancer drug Keytruda in certain...",
    "url": "https://finnhub.io/api/news?id=fe4f95cdffb8e17425987332a2f51583cd8aab13643d7ac09ef0a197a9d4d5ff",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731658214,
      "headline": "Merck Gets CHMP Backing of Keytruda in Malignant Pleural Mesothelioma",
      "id": 131369226,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its blockbuster cancer drug Keytruda in certain...",
      "url": "https://finnhub.io/api/news?id=fe4f95cdffb8e17425987332a2f51583cd8aab13643d7ac09ef0a197a9d4d5ff"
    }
  }
]